Le Lézard
Classified in: Health
Subject: PDT

Vizuri Introduces a Revolutionary New Patch to Relieve Pain


BONITA SPRINGS, Fla., Oct. 1, 2020 /PRNewswire/ -- Weekend warriors, physically active people and others needing pain relief have a new option to help relieve joint and muscle pain. Vizuri Health Sciences Consumer Healthcare Inc. ? a leader in non-opioid pain-relieving innovations ? has created a revolutionary treatment solution. New PainBloc24® Flexi-Stretch Pain Tape combines an innovative 4-way stretch patch, inspired by the lightweight, flexible fabric used in kinesiology tape, with a powerful anesthetic that helps to numb pain.

"The feedback that we hear most is surprise at how comfortable and flexible it is and that you must try it to understand how great it works," said Elise Donahue, President and CEO, VHS Consumer Healthcare. "We think this is the perfect pain relief solution for anyone with an active lifestyle or who suffers from pain anywhere in their body."

Unlike ordinary pain patches, PainBloc24 Flexi-Stretch Pain Tape uses a 4-way stretch fabric that is extremely lightweight, thin and breathable. A proprietary dry adhesive technology keeps it in place for up to 12 hours on moving joints, even while exercising. The active ingredient is 4% lidocaine, the maximum strength allowed by the U.S. Food and Drug Administration (FDA) without a prescription. Lidocaine is a numbing medication applied topically to reduce pain by blocking the body's nerve signals.

The 4-way stretch technology makes it ideal for use on moving joints, even knees and elbows.

"You just don't get this kind of flexibility and adherence with most traditional patches," added Donahue. "It's so lightweight, you don't even realize it's there. For people who use patches, topical creams or even pills to relieve their pain, this is truly innovative."

While pain patches don't always adhere well, and can be wet, messy and have strong odors, PainBloc24® Flexi-Stretch Pain Tape comes in no-mess, easy-to-use strips that are dry and have no unpleasant smell.

With a suggested retail price of $14.99, PainBloc24® Flexi-Stretch Pain Tape comes in 10 convenient precut strips. It's available nationwide at 3,000 Walgreens stores, on Amazon.com and at other retailers.

Vizuri Health Sciences Consumer Healthcare: With offices in Maryland and Florida, privately held Vizuri Health Sciences Consumer Healthcare Inc. develops superior and unique over-the-counter medicines in the pain management space that are available online and at over 25,000 retail stores. Products include the popular PainBloc24® brand of non-prescription topical pain relievers, including capsaicin-based PainBloc24® Roll-On and PainBloc24® Pain Pen. painbloc24.com

Media Contact:
Kristi Arndt, Peridot Group:
763-782-0265/cell, 612-803-0861
[email protected] 

 

SOURCE Vizuri Health Sciences


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: